Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1 21Phase 1/2 7Phase 3 5Phase NA 1Phase 4 1

Status

Completed 4Unknown 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 44Lung Neoplasms 13Pancreatic Neoplasms 5Non-Squamous Non-Small Cell Lung Cancer 5Neoplasms 4Colorectal Neoplasms 3Thoracic Neoplasms 2Respiratory Tract Diseases 2Neoplasm Metastasis 2Carcinoma 2Brain Neoplasms 2Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Solid Tumor 1Respiratory Tract Neoplasms 1Rectal Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1NSCLC 1Mouth Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Gemcitabine 73Fluorouracil 30Oxaliplatin 20Leucovorin 20130-nm albumin-bound paclitaxel 16Capecitabine 14Irinotecan 11Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × Erlotinib Hydrochloride × Clear all
NCT00026338 2020-04-02

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Canadian Cancer Trials Group

Phase 3 Completed
569 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00040183 2018-01-10

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Astellas Pharma Inc

Phase 3 Completed
569 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02694536 2017-03-24

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Hoffmann-La Roche

Phase 3 Completed
80 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00634725 2015-12-11

Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 3 Completed
820 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00440167 2012-07-09

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Ludwig-Maximilians - University of Munich

Phase 3 Unknown
280 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡